Azenta Leadership Transition
Azenta Names Martin Madaus Interim CEO Following John Marotta’s Resignation
Key Points
Dr. Martin Madaus has been a Azenta board member since January 2024 and brings more than 30 years of leadership in diagnostics and life-sciences tools, including CEO roles at Millipore, Ortho Clinical Diagnostics and Roche Diagnostics North America; he also serves as Chair of Repligen’s board and is a director at Haemonetics.
Madaus’ track record includes leading major strategic transactions, notably Millipore’s sale to Merck KGaA and Ortho Clinical Diagnostics’ leveraged buyout, underscoring his experience with large-scale corporate transformations.
Effective August 22, 2026, Azenta’s board reduced from nine to eight directors and Madaus was appointed interim President and CEO, also assuming the duties of principal executive officer for SEC reporting while remaining on the board.
During Madaus’ interim tenure, he will step down from the board’s nominating and governance committee, and the board is reviewing his compensation to reflect the expanded responsibilities.
The leadership transition occurs as Azenta emphasizes pursuing its long-range plan to deliver profitable, sustainable value while maintaining near-term operating expectations, with Heidrick & Struggles retained to search for a permanent CEO.
Azenta Inc. named Dr. Martin D. Madaus as interim President and CEO effective August 22, 2026, replacing John P. Marotta who resigned from both roles and the board MarketScreener. Madaus, a current Azenta director and senior Carlyle Group executive, brings over 30 years of experience in diagnostics and life-sciences tools, including prior CEO positions at Millipore, Ortho Clinical Diagnostics, and Roche Diagnostics North America MarketScreener.
A Proven Leader in Life Sciences Transformations
Madaus has led major corporate deals that shaped the diagnostics industry. He oversaw Millipore's sale to Merck KGaA and guided Ortho Clinical Diagnostics through a leveraged buyout MarketScreener. His track record demonstrates expertise in large-scale strategic transformations and operational execution MarketScreener.
Beyond Azenta, Madaus serves as Chair of Repligen's board and sits on Haemonetics' board, signaling confidence from other major life-sciences companies MarketScreener. He joined Azenta's board in January 2024, giving him recent familiarity with the company's business and strategy MarketScreener.
Board Shrinks and Search Begins for Permanent CEO
Azenta's board reduced in size from nine to eight directors with Madaus' appointment MarketScreener. He will serve as both interim President and CEO and assume the title of principal executive officer for SEC reporting purposes MarketScreener. During his interim tenure, Madaus steps down from the nominating and governance committee.
The board is reviewing Madaus' compensation to reflect his expanded responsibilities MarketScreener. Heidrick & Struggles, a major executive search firm, has been retained to find a permanent CEO replacement MarketScreener. No timeline for the search has been disclosed.
Financial Guidance Holds Despite One-Time Consulting Charge
Azenta reaffirmed its fourth-quarter fiscal 2026 revenue guidance despite the leadership change MarketScreener. The company disclosed a one-time consulting expense of approximately $3 million that will reduce adjusted EBITDA in the quarter MarketScreener. Excluding this charge, adjusted EBITDA guidance remains unchanged.
Chairman Frank E. Casal said the board will continue evaluating core business units for targeted reinvestment while maintaining disciplined capital deployment MarketScreener. Azenta emphasized it remains focused on executing its long-range plan to drive profitable, sustainable value creation while meeting near-term operating expectations MarketScreener.
Sentiment
Mostly PositivePublishers
10
Articles
19
Reach
29
